10 Best Small-Cap Biotech Stocks to Buy According to Hedge Funds

8. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Market Cap: $1.77 billion

Number of Hedge Fund Holders: 33

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best small-cap biotech stocks to buy according to hedge funds. The stock rose 88.76% from a year ago, while it registered a 62.32% increase year-to-date. Based on consensus, Wall Street analysts have assigned a moderate buy rating to Intellia Therapeutics stock, with an average price target of $21.25.

In a Securities and Exchange Commission (SEC) filing dated April 10, Intellia Therapeutics reported that its Board adopted amendments to the company’s Third Amended and Restated By-laws on April 7. Under the Fourth Amended and Restated By-laws, the company added a provision allowing shareholders to cure any facially apparent deficiencies in a shareholder’s timely notice of a nomination or proposal, and requiring the company to notify the shareholder of any facially apparent deficiencies in a timely notice.

The biopharmaceutical firm added that the Amended By-laws designate the federal district courts of the United States as the exclusive forum for resolving any complaint that asserts a cause of action arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the company consents in writing to the selection of an alternative forum.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine, leveraging clustered regularly interspaced short palindromic repeats (CRISPR) gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.